1. Generics Bulletin
  2. >>Products

Hikma Set For Ryaltris Take Off As Glenmark Wins USFDA Nod

Companies Partnered Up In March 2020; Ryaltris Already Rolled-Out In Europe

 
• By Dean Rudge

Glenmark is celebrating a “major milestone,” after its Ryaltris nasal spray to treat seasonal allergic rhinitis was approved by the FDA. Hikma will handle commercialization in the US, as part of its continued specialty push in the market.

Nasal_Spray
Hikma has described Ryaltris as "very interesting" • Source: Shutterstock

Hikma Pharmaceuticals’s commercialization agreement with Glenmark Pharmaceuticals in the US covering rights for the Indian firm’s Ryaltris (olopatadine hydrochloride/mometasone furoate) 665mcg/25mcg nasal spray is set to bear fruit two years after the deal was signed, following US Food and Drug Administration approval for the seasonal allergic rhinitis treatment.

Glenmark has lauded a “major milestone,” noting that its approval for the 505(b)(2) hybrid new drug application product “clearly supports our efforts to bring

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin

Pfizer Discusses Tariffs Amid International Slump For Oncology Biosimilars Revenue

 
• By Adam Zamecnik

Reflecting conversations across the wider pharmaceutical industry, Pfizer’s earnings call for the first quarter of 2025 focused on the sector’s response to the potential imposition of tariffs by the Trump administration.

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.